Efficacy of platinum chemotherapy agents in the adjuvant setting for adenosquamous carcinoma of the pancreas

Journal of Gastrointestinal Oncology

Volumn 6, Issue 2, 2015, Pages 115-125

  Wild, Aaron T ^a   Dholakia, Avani S ^a   Fan, Katherine Y ^a   Kumar, Rachit ^a   Moningi, Shalini ^a   Rosati, Lauren M ^a   Laheru, Daniel A ^a   Zheng, Lei ^a   De Jesus Acosta, Ana ^a   Ellsworth, Susannah G ^a   Hacker Prietz, Amy ^a   Voong, Khinh R ^a   Tran, Phuoc T ^a   Hruban, Ralph H ^a   Pawlik, Timothy M ^a   Wolfgang, Christopher L ^a   Herman, Joseph M ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Adenosquamous carcinoma; Adjuvant therapy; Pancreatic cancer; Platinum chemotherapy

Indexed keywords

CAPECITABINE; CISPLATIN; FLUOROURACIL; GEMCITABINE; IRINOTECAN; OXALIPLATIN; PLATINUM DERIVATIVE;

ADENOSQUAMOUS CARCINOMA; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; LYMPH NODE; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; PANCREAS ADENOSQUAMOUS CARCINOMA; PANCREAS CANCER; PANCREAS RESECTION; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; SALVAGE THERAPY; TUMOR VOLUME;

EID: 84995747513     PISSN: 20786891     EISSN: 2219679X     Source Type: Journal    
DOI: 10.3978/j.issn.2078-6891.2014.091     Document Type: Article

References (43)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63:11-30.
2. Sener SF, Fremgen A, Menck HR, et al. Pancreatic cancer: a report of treatment and survival trends for 100, 313 patients diagnosed from 1985-1995, using the National Cancer Database. J Am Coll Surg 1999;189:1-7.
3. Tempero MA, Arnoletti JP, Behrman SW, et al. Pancreatic Adenocarcinoma, version 2.2012: featured updates to the NCCN Guidelines. J Natl Compr Canc Netw 2012;10:703-13.
4. Cihak RW, Kawashima T, Steer A. Adenoacanthoma (adenosquamous carcinoma) of the pancreas. Cancer 1972;29:1133-40.
5. Cubilla AL, Fitzgerald PJ. Morphological patterns of primary nonendocrine human pancreas carcinoma. Cancer Res 1975;35:2234-48.
6. Hsu JT, Yeh CN, Chen YR, et al. Adenosquamous carcinoma of the pancreas. Digestion 2005;72:104-8.
7. Kardon DE, Thompson LD, Przygodzki RM, et al. Adenosquamous carcinoma of the pancreas: a clinicopathologic series of 25 cases. Mod Pathol 2001;14:443-51.
8. Madura JA, Jarman BT, Doherty MG, et al. Adenosquamous carcinoma of the pancreas. Arch Surg 1999;134:599-603.
9. Hruban RH, Pitman MB, Klimstra DS. Tumors of the pancreas. AFIP Atlas of Tumor Pathology 2007:177-81.
10. Voong KR, Davison J, Pawlik TM, et al. Resected pancreatic adenosquamous carcinoma: clinicopathologic review and evaluation of adjuvant chemotherapy and radiation in 38 patients. Hum Pathol 2010;41:113-22.
11. Herman JM, Swartz MJ, Hsu CC, et al. Analysis of fluorouracil-based adjuvant chemotherapy and radiation after pancreaticoduodenectomy for ductal adenocarcinoma of the pancreas: results of a large, prospectively collected database at the Johns Hopkins Hospital. J Clin Oncol 2008;26:3503-10.
12. Katz MH, Taylor TH, Al-Refaie WB, et al. Adenosquamous versus adenocarcinoma of the pancreas: a population-based outcomes analysis. J Gastrointest Surg 2011;15:165-74.
13. Boyd CA, Benarroch-Gampel J, Sheffield KM, et al. 415 patients with adenosquamous carcinoma of the pancreas: a population-based analysis of prognosis and survival. J Surg Res 2012;174:12-9.
14. Smoot RL, Zhang L, Sebo TJ, et al. Adenosquamous carcinoma of the pancreas: a single-institution experience comparing resection and palliative care. J Am Coll Surg 2008;207:368-70.
15. Yamaguchi K, Enjoji M. Adenosquamous carcinoma of the pancreas: a clinicopathologic study. J Surg Oncol 1991;47:109-16.
16. Brody JR, Costantino CL, Potoczek M, et al. Adenosquamous carcinoma of the pancreas harbors KRAS2, DPC4 and TP53 molecular alterations similar to pancreatic ductal adenocarcinoma. Mod Pathol 2009;22:651-9.
17. Motojima K, Tomioka T, Kohara N, et al. Immunohistochemical characteristics of adenosquamous carcinoma of the pancreas. J Surg Oncol 1992;49:58-62.
18. Hsu JT, Chen HM, Wu RC, et al. Clinicopathologic features and outcomes following surgery for pancreatic adenosquamous carcinoma. World J Surg Oncol 2008;6:95.
19. Yamaue H, Tanimura H, Onishi H, et al. Adenosquamous carcinoma of the pancreas: successful treatment with extended radical surgery, intraoperative radiation therapy, and locoregional chemotherapy. Int J Pancreatol 2001;29:53-8.
20. Matsubayashi H, Matsunaga K, Uesaka K, et al. Pancreatic adenosquamous carcinoma with 7-year survival: a case report and literature review. J Dig Dis 2013;14:207-10.
21. Trikudanathan G, Dasanu CA. Adenosquamous carcinoma of the pancreas: a distinct clinicopathologic entity. South Med J 2010;103:903-10.
22. Wolfgang CL, Herman JM, Laheru DA, et al. Recent progress in pancreatic cancer. CA Cancer J Clin 2013;63:318-48.
23. Bergman AM, Ruiz van Haperen VW, Veerman G, et al. Synergistic interaction between cisplatin and gemcitabine in vitro. Clin Cancer Res 1996;2:521-30.
24. Van Moorsel CJ, Pinedo HM, Veerman G, et al. Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small-cell lung cancer cell lines. Br J Cancer 1999;80:981-90.
25. Yang LY, Li L, Jiang H, et al. Expression of ERCC1 antisense RNA abrogates gemicitabine-mediated cytotoxic synergism with cisplatin in human colon tumor cells defective in mismatch repair but proficient in nucleotide excision repair. Clin Cancer Res 2000;6:773-81.
26. Ando N, Iizuka T, Ide H, et al. Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus: a Japan Clinical Oncology Group Study--JCOG9204. J Clin Oncol 2003;21:4592-6.
27. Enzinger PC, Ilson DH, Kelsen DP. Chemotherapy in esophageal cancer. Semin Oncol 1999;26:12-20.
28. Bae WK, Hwang JE, Shim HJ, et al. Multicenter phase II study of weekly docetaxel, cisplatin, and S-1 (TPS) induction chemotherapy for locally advanced squamous cell cancer of the head and neck. BMC Cancer 2013;13:102.
29. Schwartz DL, Montgomery RB, Yueh B, et al. Phase I and initial phase II results from a trial investigating weekly docetaxel and carboplatin given neoadjuvantly and then concurrently with concomitant boost radiotherapy for locally advanced squamous cell carcinoma of the head and neck. Cancer 2005;103:2534-43.
30. Amrein PC, Weitzman SA. Treatment of squamouscell carcinoma of the head and neck with cisplatin and 5-fluorouracil. J Clin Oncol 1985;3:1632-9.
31. Rabbani A, Hinerman RW, Schmalfuss IM, et al. Radiotherapy and concomitant intraarterial cisplatin (RADPLAT) for advanced squamous cell carcinomas of the head and neck. Am J Clin Oncol 2007;30:283-6.
32. Lambert HE, Berry RJ. High dose cisplatin compared with high dose cyclophosphamide in the management of advanced epithelial ovarian cancer (FIGO stages III and IV): report from the North Thames Cooperative Group. Br Med J (Clin Res Ed) 1985;290:889-93.
33. Neijt JP, ten Bokkel Huinink WW, van der Burg ME, et al. Randomised trial comparing two combination chemotherapy regimens (Hexa-CAF vs CHAP-5) in advanced ovarian carcinoma. Lancet 1984;2:594-600.
34. Williams CJ, Mead GM, Macbeth FR, et al. Cisplatin combination chemotherapy versus chlorambucil in advanced ovarian carcinoma: mature results of a randomized trial. J Clin Oncol 1985;3:1455-62.
35. Omura G, Blessing JA, Ehrlich CE, et al. A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma. A Gynecologic Oncology Group Study. Cancer 1986;57:1725-30.
36. Colucci G, Giuliani F, Gebbia V, et al. Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologia dell'Italia Meridionale. Cancer 2002;94:902-10.
37. Colucci G, Labianca R, Di Costanzo F, et al. Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study. J Clin Oncol 2010;28:1645-51.
38. Aurilio G, Macarulla T, Ramos JF, et al. Successful treatment with GEMOX in patient with metastatic pancreatic adenosquamous carcinoma. Tumori 2011;97:239-42.
39. Shibagaki K, Fujita K, Nakayama S, et al. Complete response of a pancreatic adenosquamous carcinoma to chemoradiotherapy. Int J Clin Oncol 2008;13:74-7.
40. Hu XJ, Lagakos SW. Nonparametric estimation of the mean function of a stochastic process with missing observations. Lifetime Data Anal 2007;13:51-73.
41. Cox DR. Regression models and life-tables. J R Stat Soc Ser 1972;34:187-220.
42. Regine WF, Winter KA, Abrams RA, et al. Fluorouracil vs gemcitabine chemotherapy before and after fluorouracilbased chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial. JAMA 2008;299:1019-26.
43. Burris HA 3rd, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as firstline therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997;15:2403-13.